Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib beyond progression in EGFR-mutant NSCLC
NCT02064491Phase 2Completed
- Sponsor
- Finnish Lung Cancer Group
- Start
- Feb 2014
- Primary completion
- Dec 2016
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Finnish Lung Cancer Group. Started Feb 2014; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02064491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02064491.